Selsym Biotech Inc.

Cary, NC

UEI
G522J2NEDHD2
CAGE
8JGX8
Primary NAICS
541714 Research and Development in Biotechnology (except Nanobiotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Self Certified Small Disadvantaged Business
  • For Profit Organization
  • Woman Owned Small Business
  • Woman Owned Business
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
101 Linecrest Ct, Cary, NC 27518, USA
Website
selsymbio.com
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Symclot: synthetic platelet mimetic particles for augmenting hemostasis in patients requiring extracorporeal support HT94252310977 Defense Health Agency $1,996,885
Symheal: a novel therapy for treating non-healing diabetic ulcers R41DK135288 National Institute of Diabetes and Digestive and Kidney Diseases (NIH) $458,948
Increasing efficiency of sdfv production in a tobacco-based system for synthetic platelet design R41HL162242 National Heart Lung and Blood Institute (NIH) $258,501
Evaluation of stability and safety of platelet-like particles for treating bleeding after trauma R41HL156763 National Heart Lung and Blood Institute (NIH) $1,019,512

Grant subawards

Prime recipient Prime award Amount Awarded
North Carolina State University During the course of this project, SelSym Biotech will provide hands-on consultation and translational collaboration to Dr. Brown’s team centered around scalale… HT9425261E109 $262,150

Similar vendors

Vendor Location Primary NAICS
Cellphire, Inc. UEI F42VPQJ8LJL4 Rockville, MD 541714 Research and Development in Biotechnology (except Nanobiotechnology)
Haima Therapeutics LLC UEI JKZPL4NA9V21 Cleveland, OH 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Stasys Medical Corp UEI SQX6FKMNWVV7 Kirkland, WA —
Fibroplate Inc. UEI UKBYP1UTHBK1 Las Vegas, NV 325414 Biological Product (except Diagnostic) Manufacturing
Coalesenz Inc. UEI J2FNAFKMP664 Cambridge, MA 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Selsym Biotech Inc. is a woman-owned small business and for-profit corporate entity. It is involved in developing synthetic platelet mimetic technologies for applications in treating bleeding, clotting disorders, and wound healing.

Selsym Biotech has received several federal grants to support its work on synthetic platelet-like particles (PLPs) and related technologies. A recent $1.9 million award from the Defense Health Agency funds development of PLPs called SYMCLOT for augmenting hemostasis in patients requiring extracorporeal support like those with battlefield injuries. The National Institute of Diabetes and Digestive and Kidney Diseases provided $458,948 to develop SYMHEAL, PLPs combined with growth factors for treating non-healing diabetic ulcers. The National Heart, Lung and Blood Institute awarded $258,501 to optimize antibody fragment yield in a plant expression system to scale up PLP production, and $1 million to evaluate long-term PLP stability and maximum tolerated dose for trauma care. These grants demonstrate Selsym's extensive research across military, emergency medicine, and diabetic wound healing applications leveraging its core synthetic platelet technology under programs like Military Medical Research and Development, Extramural Research in Diabetes and Kidney Diseases, and Cardiovascular Sciences.

Quick answers

Is Selsym Biotech Inc. registered in SAM.gov?

Yes. Selsym Biotech Inc.'s SAM.gov registration is active through May 31, 2027.

What is Selsym Biotech Inc.'s CAGE code?

Selsym Biotech Inc.'s CAGE code is 8JGX8, and its Unique Entity ID (UEI) is G522J2NEDHD2.

What is Selsym Biotech Inc.'s most recent federal award?

Selsym Biotech Inc.'s most recent federal grant award is Symclot: synthetic platelet mimetic particles for augmenting hemostasis in patients requiring extracorporeal support (HT94252310977), from Defense Health Agency, on September 30, 2023.

On GovTribe

See Selsym Biotech Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe